Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.02M | 4.48M | 7.99M | 28.93M | 15.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.02M | 4.48M | 7.99M | 28.93M | 15.56M |
| Cost of Revenue | 140.15M | 141.41M | 118.92M | 125.31M | 100.25M |
| Gross Profit | -131.14M | -136.93M | -110.93M | -96.38M | -84.68M |
| SG&A Expenses | 132.35M | 117.18M | 92.99M | 169.62M | 100.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 272.50M | 258.59M | 211.91M | 294.93M | 201.22M |
| Operating Income | -263.48M | -254.11M | -203.92M | -266.00M | -185.66M |
| Income Before Tax | -234.51M | -224.38M | -19.64M | -191.45M | 5.15B |
| Income Tax Expenses | -25.57M | 12.46M | 11.96M | -8.96M | 22.37M |
| Earnings from Continuing Operations | -208.95M | -236.84M | -31.60M | -182.50M | 5.13B |
| Earnings from Discontinued Operations | 327.02M | -43.08M | 89.09M | -- | -58.52M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 51.31M | 49.74M | 37.81M | 31.38M | 23.52M |
| Net Income | 169.38M | -230.18M | 95.30M | -151.12M | 5.10B |
| EBIT | -263.48M | -254.11M | -203.92M | -266.00M | -185.66M |
| EBITDA | -261.54M | -252.13M | -199.04M | -260.78M | -183.14M |
| EPS Basic | 0.23 | -0.31 | 0.13 | -0.19 | 6.37 |
| Normalized Basic EPS | -0.10 | -0.09 | -0.06 | -0.13 | -0.09 |
| EPS Diluted | 0.23 | -0.31 | 0.12 | -0.19 | 6.03 |
| Normalized Diluted EPS | -0.10 | -0.09 | -0.06 | -0.13 | -0.08 |
| Average Basic Shares Outstanding | 722.72M | 735.47M | 735.81M | 802.86M | 800.59M |
| Average Diluted Shares Outstanding | 722.72M | 735.47M | 735.81M | 802.86M | 844.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
